BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 27617853)

  • 1. Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study.
    Azoulay D; Audureau E; Bhangui P; Belghiti J; Boillot O; Andreani P; Castaing D; Cherqui D; Irtan S; Calmus Y; Chazouillères O; Soubrane O; Luciani A; Feray C
    Ann Surg; 2017 Dec; 266(6):1035-1044. PubMed ID: 27617853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses.
    Wong TCL; Ng KKC; Fung JYY; Chan AAC; Cheung TT; Chok KSH; Dai JWC; Lo CM
    Ann Surg Oncol; 2019 May; 26(5):1454-1462. PubMed ID: 30737669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation.
    Bhangui P; Vibert E; Majno P; Salloum C; Andreani P; Zocrato J; Ichai P; Saliba F; Adam R; Castaing D; Azoulay D
    Hepatology; 2011 May; 53(5):1570-9. PubMed ID: 21520172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.
    Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y
    J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical management of hepatocellular carcinoma in Child-Pugh class B cirrhotic patients: hepatic resection and/or microwave coagulation therapy versus living donor liver transplantation.
    Harada N; Shirabe K; Ikeda Y; Korenaga D; Takenaka K; Maehara Y
    Ann Transplant; 2012 Dec; 17(4):11-20. PubMed ID: 23274319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
    Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
    Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor liver transplantation for hepatocellular carcinoma.
    Lee SG; Moon DB
    Recent Results Cancer Res; 2013; 190():165-79. PubMed ID: 22941020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation.
    Hu Z; Qian Z; Wu J; Zhou J; Zhang M; Zhou L; Zheng S
    Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):315-326. PubMed ID: 26382281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.
    Lai Q; Sapisochin G; Gorgen A; Vitale A; Halazun KJ; Iesari S; Schaefer B; Bhangui P; Mennini G; Wong TCL; Uemoto S; Lin CC; Mittler J; Ikegami T; Yang Z; Frigo AC; Zheng SS; Soejima Y; Hoppe-Lotichius M; Chen CL; Kaido T; Lo CM; Rossi M; Soin AS; Finkenstedt A; Emond JC; Cillo U; Lerut JP
    JAMA Surg; 2021 Sep; 156(9):e213112. PubMed ID: 34259797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
    Sandhu L; Sandroussi C; Guba M; Selzner M; Ghanekar A; Cattral MS; McGilvray ID; Levy G; Greig PD; Renner EL; Grant DR
    Liver Transpl; 2012 Mar; 18(3):315-22. PubMed ID: 22140013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
    Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
    Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study on the outcome of patients with hepatocellular carcinoma registered for living donor liver transplantation: how long can they wait?
    Mizuno S; Yokoi H; Shiraki K; Usui M; Sakurai H; Tabata M; Sugimoto K; Takei Y; Yamakado K; Takeda K; Uemoto S; Isaji S
    Transplantation; 2010 Mar; 89(6):650-4. PubMed ID: 20048691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations.
    Hwang S; Lee SG; Joh JW; Suh KS; Kim DG
    Liver Transpl; 2005 Oct; 11(10):1265-72. PubMed ID: 16184545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End-Stage Liver Disease and Hepatorenal Syndrome.
    Wong TC; Fung JY; Pang HH; Leung CK; Li HF; Sin SL; Ma KW; She BW; Dai JW; Chan AC; Cheung TT; Lo CM
    Hepatology; 2021 Jun; 73(6):2441-2454. PubMed ID: 33006772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.